Skip to contentF
Fulcrum Therapeutics, Inc.
F
FULCFulcrum Therapeutics, Inc. Q1 2025 · 10-Q
Revenue—
Net Income-$17.66M-$17.66MN/M vs Q1 2024 EPS Diluted-$0.28-$0.28N/M vs Q1 2024 Operating Income-$20,403,000N/M Operating Cash Flow-$15,257,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
Free Cash Flowderived-$15,257,000N/M ended Mar 31, 2025 · filed May 1, 2025 · 31 d after period end